(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.75%) $83.22
(-1.16%) $1.619
(-0.05%) $2 346.10
(-0.18%) $27.49
(0.27%) $924.60
(-0.11%) $0.934
(-0.10%) $11.01
(-0.17%) $0.799
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.47%
@ $8.24
Išleistas: 14 vas. 2024 @ 22:41
Grąža: -36.13%
Ankstesnis signalas: vas. 13 - 22:50
Ankstesnis signalas:
Grąža: 3.45 %
Live Chart Being Loaded With Signals
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases...
Stats | |
---|---|
Šios dienos apimtis | 1.22M |
Vidutinė apimtis | 1.21M |
Rinkos kapitalizacija | 400.28M |
EPS | $0 ( 2024-02-15 ) |
Kita pelno data | ( $-0.950 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.00800 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Cline Christopher R. | Sell | 54 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 135 000 | Common Stock |
2024-02-01 | Dube Eric M | Sell | 9 106 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 360 000 | Employee stock option (right to buy) |
2024-02-01 | Dube Eric M | Sell | 10 016 | Common Stock |
INSIDER POWER |
---|
89.25 |
Last 100 transactions |
Buy: 2 015 500 | Sell: 106 721 |
Tūris Koreliacija
Travere Therapeutics, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Travere Therapeutics, Koreliacija - Valiuta/Žaliavos
Travere Therapeutics, Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $145.24M |
Bruto pelnas: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2023 |
Pajamos: | $145.24M |
Bruto pelnas: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2022 |
Pajamos: | $212.02M |
Bruto pelnas: | $204.43M (96.42 %) |
EPS: | $-4.37 |
FY | 2021 |
Pajamos: | $227.49M |
Bruto pelnas: | $220.71M (97.02 %) |
EPS: | $-3.79 |
Financial Reports:
No articles found.
Travere Therapeutics,
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.